Skip to content

Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium

Effect of Sildenafil on Uterine and Endometrial Vasculature in Women With Thin Endometrium Having Frozen-Thawed IVF Cycles

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04283435
Enrollment
100
Registered
2020-02-25
Start date
2021-09-01
Completion date
2022-03-01
Last updated
2021-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Receptivity, IVF

Brief summary

Management of Thin endometrium in IVF is challenging. Thin endometrium is often defined as \<7 mm or \< 8 mm on the day of Human Gonadotropin administration(Bu and Sun, 2015; Wu et al., 2014). Its incidence is 1-2.5% in most studies ( AlGhamdi et al.,2008). Endometrial thickness and endometrial vascularity is closely linked to endometrial receptivity.Improving endometrial receptivity is a predictor of the success in IVF. Many medications have been tried to improve endometrial thickness as Aspirin,sildenafil citrate,luteal estradiol and Granulocyte colony stimulating factor. Nitric oxide (NO) is a key signaling molecule involved in the vasodilator response of smooth muscle cells. NO activates the cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) pathway within smooth muscle cells to promote smooth muscle cell relaxation. Sildenafil citrate inhibits phosphodiesterase 5 (PDE5) maintaining activation of cGMP and PKG and maximizing the effect of existing NO, thus facilitating smooth muscle cell relaxation. The potent vasodilator action of sildenafil has led researchers to evaluate sildenafil as a treatment in assisted reproduction where low uterine blood flow is perceived to be a contributor to implantation failure (Fairouzabadi et al.2013). The investigators aim at this study to investigate the role of sildenafil citrate on endometrial and subendometrial vasculature in women with thin endometrium undergoing Frozen-Thawed IVF cycles.

Detailed description

This is a Randomised-controlled trial .The investigators recruited 100 women who are known to have thin endometrium in previous IVF cycles (failed/cancelled cycles). They are randomised into group A (50 women) : preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova,Payer,Germany) from the first day of the cycle till 12th day and The investigators add placebo from the first day of the cycle till the day of starting progesterone (It will be stopped 3 days before embryo transfer).Group B (50 women): The investigators add Sildenafil citrate (Viagra,pfizer,United states) to the estradiol valerate. Sildenafil 50 mg will be used daily from the first day of the cycle till the day of starting progesterone (It will be stopped 3 days before embryo transfer). The embryos will be transferred depending on their age on day 3 or day 5. At the transfer date ,the investigators will assess the endometrial thickness, endometrial volume, uterine artery doppler indices (RI,PI) as well as 3D endometrial vascular indices (VI,FI,VFI) .

Interventions

DRUGSildenafil Citrate

Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)

OTHERPlacebo

Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)

DRUGEstradiol Valerate

Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

One hundred envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside.

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women (25 -40 years) undergoing IVF frozen-Thawed cycles and known to have good quality embryos. * previous thin endometrium (\< 8mm on at least 3 previous cycles) with normal Hysteroscopy findings

Exclusion criteria

* women less than 25 years old or more than 40 years old. * abnormal hysteroscopic findings. * women with congenital uterine anomalies. * History of previous uterine surgery * Any contraindication to Sildenafil as Previous history of cardiac disease or stroke.

Design outcomes

Primary

MeasureTime frame
Clinical Pregnancy rate2 weeks after embryo transfer

Secondary

MeasureTime frame
endometrial thicknessat the time of embryo transfer
Endometrial volumeat the time of embryo transfer
Uterine artery doppler indicesat the time of embryo transfer
3D endometrial and subendometrial vascular indices(VI,FI.VFI)at the time of embryo transfer

Countries

Egypt

Contacts

Primary ContactEman Elkattan, MD
emyelkattan@gmail.com01212529213
Backup Contactwafaa Ramadan, MD
01019944328

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026